CCNO Gene Primary Ciliary Dyskinesia Type 29 NGS Genetic DNA Test
Comprehensive Genetic Analysis for Respiratory Health
The CCNO Gene Primary Ciliary Dyskinesia Type 29 NGS Genetic DNA Test represents a cutting-edge diagnostic approach for identifying genetic mutations associated with Primary Ciliary Dyskinesia (PCD) Type 29. This specialized genetic test provides crucial insights into the underlying causes of chronic respiratory conditions and helps guide personalized treatment strategies for affected individuals and families.
What This Advanced Genetic Test Detects
Our comprehensive NGS-based genetic analysis specifically targets mutations in the CCNO gene, which plays a critical role in the development and function of motile cilia throughout the body. The test identifies:
- Pathogenic variants in the CCNO gene sequence
- Missense, nonsense, and frameshift mutations
- Copy number variations affecting ciliary function
- Inheritance patterns for family risk assessment
- Specific genetic markers associated with PCD Type 29
Who Should Consider This Genetic Testing
This specialized genetic test is recommended for individuals experiencing:
- Chronic respiratory symptoms beginning in infancy or early childhood
- Recurrent sinus infections and persistent nasal congestion
- Frequent middle ear infections requiring multiple treatments
- Unexplained chronic cough and bronchiectasis
- Neonatal respiratory distress without clear cause
- Laterality defects such as situs inversus
- Unexplained infertility or ectopic pregnancy history
- Family history of Primary Ciliary Dyskinesia
Significant Benefits of Genetic Testing
Undergoing the CCNO Gene PCD Type 29 test provides numerous advantages:
- Accurate Diagnosis: Confirms or rules out genetic causes of respiratory symptoms
- Personalized Treatment: Enables targeted therapies based on specific genetic findings
- Family Planning: Provides crucial information for reproductive decisions
- Early Intervention: Facilitates proactive management of respiratory complications
- Genetic Counseling: Supports informed decisions about family health risks
- Comprehensive Care: Coordinates with ENT specialists and pulmonologists
Understanding Your Test Results
Our genetic specialists provide detailed interpretation of your results:
- Positive Result: Indicates presence of CCNO gene mutations associated with PCD Type 29, requiring specialized medical management
- Negative Result: Suggests absence of tested CCNO mutations, though other genetic or environmental factors may contribute to symptoms
- Variant of Uncertain Significance: Requires additional family studies and clinical correlation
- Carrier Status: Identifies individuals who may pass the condition to offspring
Test Pricing and Availability
| Test Component | Price (USD) |
|---|---|
| Discount Price | $500 |
| Regular Price | $700 |
Nationwide Testing Availability
We proudly offer comprehensive genetic testing services across the United States, with convenient locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many other cities. Our network of certified genetic counselors and medical professionals ensures accessible, high-quality care regardless of your location.
Take Control of Your Respiratory Health Today
Don’t let unexplained respiratory symptoms or family history concerns go unaddressed. Our CCNO Gene Primary Ciliary Dyskinesia Type 29 NGS Genetic DNA Test provides the clarity you need for effective health management. With results available in 3-4 weeks and multiple sample collection options including blood, extracted DNA, or blood spots on FTA cards, getting tested has never been more convenient.
Ready to take the next step toward genetic clarity? Call our dedicated genetic counseling team at +1(267) 388-9828 to schedule your appointment or discuss testing options. Our specialists are available to answer your questions and guide you through the testing process with compassion and expertise.
